ID
RPRX

Integral Derivatives’s Repros Therapeutics Inc. RPRX Stock Holding History

Integral Derivatives’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-35,266
Closed -$352K – 1643
2014
Q4 		$352K Buy
+35,266
New +$301K 0.01% 1025

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Integral Derivatives's RPRX Position: Q1 2015 in Review

Integral Derivatives sold out of Repros Therapeutics Inc. (RPRX) in Q1 2015, closing a stake of 35,266 shares — an estimated $352K sold.

Integral Derivatives first reported a position in RPRX in Q4 2014 and held it in 1 quarter. The position peaked at $352K in Q4 2014. 72 funds tracked by Wall St. Rank hold RPRX as of Q1 2015.

  • Integral Derivatives reported no remaining Repros Therapeutics Inc. position as of Q1 2015 after selling out during the quarter.
  • Integral Derivatives sold 35,266 Repros Therapeutics Inc. shares in Q1 2015, an estimated $352K.
  • Integral Derivatives first reported a position in Repros Therapeutics Inc. in Q4 2014 and held it in 1 quarter.
  • Integral Derivatives's Repros Therapeutics Inc. position peaked at $352K in Q4 2014.
  • 72 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2015.

Based on Integral Derivatives's 13F filing for Q1 2015, filed 20 Apr 2015.